Table 2.

SBP and renal excretory responses to 2-wk ANG II infusion (1.5 mg·kg⁻¹·day⁻¹ iv) or concurrent administration of ANG II and the ANG II type 1 receptor blocker losartan in WT and CAV-1 KO mice

	WT Mice			CAV-1 KO Mice
Responses	Control	ANG II	ANG II + losartan	Control	ANG II	ANG II + losartan
Number of mice/group	10	11	10	11	11	7
SBP, mmHg	113 ± 2	167 ± 4b	121 ± 4d	122 ± 3e	153 ± 3be	112 ± 4c
Kidney-to-body weight ratio, ×100	0.59 ± 0.02	0.68 ± 0.05b	0.63 ± 0.0	0.72 ± 0.06	0.71 ± 0.02	0.61 ± 0.02
Drinking, ml/24 h	3.5 ± 0.2	5.6 ± 0.9b	3.5 ± 0.2d	3.3 ± 0.7	3.1 ± 0.5f	5.8 ± 0.3ade
Urine, ml/24 h	1.2 ± 0.1	2.9 ± 0.2b	1.2 ± 0.1d	1.3 ± 0.2	1.3 ± 0.2f	1.1 ± 0.2
Urinary Na+ excretion, μmol/24 h	203.8 ± 5.2	260.5 ± 9.8	213.7.2 ± 12.3	210.2 ± 10.2	170.5 ± 3.6be	257.0 ± 15.9c
Urinary K+ excretion, μmol/24 h	408.7 ± 9.8	335.0 ± 12.6	416.9.3 ± 15.2	293.8 ± 16.4	226.6 ± 4.3e	354.3 ± 16.9

Values are means ± SE.

^aP < 0.05 and

^bP < 0.01 vs. control;

^cP < 0.05 and

^dP < 0.01 vs. ANG II;

^eP < 0.05 and

^fP < 0.01 vs. WT mice that received the same treatment.